Guillermo Lay-Son
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guillermo Lay-Son has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Gabriela M. Repetto
Rare Diseases Program, Center for Genetics and Genomics, Institute of Science and Innovation in Medicine, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile
9 shared publications Karena Espinoza
Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile
4 shared publicationsAlonso Puga
3 shared publicationsMariana Aracena
Genetics Unit, Hospital Dr Luis Calvo Mackenna, Santiago, Chile
3 shared publicationsMirta Palomares
Fundación Gantz, Santiago, Chile
3 shared publications- Víctor Faundes
Laboratorio de Genética y Enfermedades Metabólicas, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Santiago, Chile
3 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 97 (4)
Hernia Diafragmática Congénita: comparación entre formas aisladas y sindrómicas
La Hernia Diafragmática Congénita (HDC) afecta a 1 de cada 3.000 recién nacidos vivos y se asocia a una morbilidad y mortalidad significativas, especialmente cuando coexiste con otras anomalías congénitas o es parte de un síndrome genético. Objetivo: Comparar las características clínicas y la evolución hospitalaria de los recién nacidos con HDC aislada y HDC sindrómica. Pacientes y Método: Se analizaron datos de recién nacidos vivos con HDC atendidos entre 2013 y 2024. Los casos se clasificaron como HDC aislada o HDC compleja (con anomalías asociadas); estas últimas se subdividieron en sindrómicas (síndrome genético confirmado o sospechado) y no sindrómicas. Se evaluaron variables perinatales, características del defecto y evolución hospitalaria. Para la comparación se usaron prueba exacta de Fisher, t de Student o Mann-Whitney U, y regresión logística para estimar razón de odds (OR) con intervalos de confianza del 95%. Resultados: Se registraron 366 casos: 193 (52,7%) aislados y 173 (47,3%) complejos, de los cuales 78 (21,3%) fueron sindrómicos y 28 confir mados genéticamente. Los síndromes más frecuentes fueron Down, Turner, trisomía 9 en mosaico, Emanuel y Wolf-Hirschhorn. Los pacientes sindrómicos presentaron menor edad gestacional, mayor frecuencia de HDC derecha, menor uso de ECMO, menor supervivencia y hospitalizaciones más prolongadas. Las cardiopatías congénitas fueron la anomalía asociada más común. Conclusiones: Las HDC sindrómicas muestran mayor complejidad clínica, menor supervivencia y estancias más largas en comparación con las aisladas. Estos hallazgos refuerzan la importancia de la evaluación genética sistemática para precisar diagnóstico, establecer pronóstico y optimizar decisiones terapéuticas.
- 23 June 2026
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 97 (4)
Open AccessHernia Diafragmática Congénita: comparación entre formas aisladas y sindrómicas
La Hernia Diafragmática Congénita (HDC) afecta a 1 de cada 3.000 recién nacidos vivos y se asocia a una morbilidad y mortalidad significativas, especialmente cuando coexiste con otras anomalías congénitas o es parte de un síndrome genético. Objetivo: Comparar las características clínicas y la evolución hospitalaria de los recién nacidos con HDC aislada y HDC sindrómica. Pacientes y Método: Se analizaron datos de recién nacidos vivos con HDC atendidos entre 2013 y 2024. Los casos se clasificaron como HDC aislada o HDC compleja (con anomalías asociadas); estas últimas se subdividieron en sindrómicas (síndrome genético confirmado o sospechado) y no sindrómicas. Se evaluaron variables perinatales, características del defecto y evolución hospitalaria. Para la comparación se usaron prueba exacta de Fisher, t de Student o Mann-Whitney U, y regresión logística para estimar razón de odds (OR) con intervalos de confianza del 95%. Resultados: Se registraron 366 casos: 193 (52,7%) aislados y 173 (47,3%) complejos, de los cuales 78 (21,3%) fueron sindrómicos y 28 confir mados genéticamente. Los síndromes más frecuentes fueron Down, Turner, trisomía 9 en mosaico, Emanuel y Wolf-Hirschhorn. Los pacientes sindrómicos presentaron menor edad gestacional, mayor frecuencia de HDC derecha, menor uso de ECMO, menor supervivencia y hospitalizaciones más prolongadas. Las cardiopatías congénitas fueron la anomalía asociada más común. Conclusiones: Las HDC sindrómicas muestran mayor complejidad clínica, menor supervivencia y estancias más largas en comparación con las aisladas. Estos hallazgos refuerzan la importancia de la evaluación genética sistemática para precisar diagnóstico, establecer pronóstico y optimizar decisiones terapéuticas.
- 29 May 2024
- Published by Wolters Kluwer Health in Clinical Dysmorphology
- Vol. 33 (3) , 105-109
Silver-Russell syndrome-like features in a child with recombinant chromosome 11 derived from maternal pericentric inversion
Silver-Russell syndrome (SRS) is a well-known syndrome but with heterogeneous etiologies. We present the case of a child with severe SRS-like features resulting from a complex rearrangement of chromosome 11 inherited from his mother. We studied the index case with karyotyping, MS-MLPA and molecular karyotyping. The mother was studied with karyotyping and subtelomeric FISH. We found a child with marked developmental delay and fatal outcome due to failure to thrive, carrying an 11p15 duplication and an 11q25 deletion of maternal origin. We discovered that the mother was a carrier of a pericentric inversion of chromosome 11, with a history of recurrence in other family members who had severe growth retardation and early death. To our knowledge, no similar SRS-like cases have been described in the literature. This report supports the importance of identification the causative genetic mechanism in SRS-like individuals with duplication in 11p15 region due to high risk of recurrence and to provide an appropriate genetic counseling to the family.
- 29 May 2024
- Published by Wolters Kluwer Health in Clinical Dysmorphology
- Vol. 33 (3) , 105-109
Silver-Russell syndrome-like features in a child with recombinant chromosome 11 derived from maternal pericentric inversion
Silver-Russell syndrome (SRS) is a well-known syndrome but with heterogeneous etiologies. We present the case of a child with severe SRS-like features resulting from a complex rearrangement of chromosome 11 inherited from his mother. We studied the index case with karyotyping, MS-MLPA and molecular karyotyping. The mother was studied with karyotyping and subtelomeric FISH. We found a child with marked developmental delay and fatal outcome due to failure to thrive, carrying an 11p15 duplication and an 11q25 deletion of maternal origin. We discovered that the mother was a carrier of a pericentric inversion of chromosome 11, with a history of recurrence in other family members who had severe growth retardation and early death. To our knowledge, no similar SRS-like cases have been described in the literature. This report supports the importance of identification the causative genetic mechanism in SRS-like individuals with duplication in 11p15 region due to high risk of recurrence and to provide an appropriate genetic counseling to the family.
- Open Access
- 4 January 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (10) , 1227-1237
Decoding complex inherited phenotypes in rare disorders: the DECIPHERD initiative for rare undiagnosed diseases in Chile
Rare diseases affect millions of people worldwide, and most have a genetic etiology. The incorporation of next-generation sequencing into clinical settings, particularly exome and genome sequencing, has resulted in an unprecedented improvement in diagnosis and discovery in the past decade. Nevertheless, these tools are unavailable in many countries, increasing health care gaps between high- and low-and-middle-income countries and prolonging the “diagnostic odyssey” for patients. To advance genomic diagnoses in a setting of limited genomic resources, we developed DECIPHERD, an undiagnosed diseases program in Chile. DECIPHERD was implemented in two phases: training and local development. The training phase relied on international collaboration with Baylor College of Medicine, and the local development was structured as a hybrid model, where clinical and bioinformatics analysis were performed in-house and sequencing outsourced abroad, due to lack of high-throughput equipment in Chile. We describe the implementation process and findings of the first 103 patients. They had heterogeneous phenotypes, including congenital anomalies, intellectual disabilities and/or immune system dysfunction. Patients underwent clinical exome or research exome sequencing, as solo cases or with parents using a trio design. We identified pathogenic, likely pathogenic or variants of unknown significance in genes related to the patients´ phenotypes in 47 (45.6%) of them. Half were de novo informative variants, and half of the identified variants have not been previously reported in public databases. DECIPHERD ended the diagnostic odyssey for many participants. This hybrid strategy may be useful for settings of similarly limited genomic resources and lead to discoveries in understudied populations.
- 4 January 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (10) , 1227-1237
Open AccessDecoding complex inherited phenotypes in rare disorders: the DECIPHERD initiative for rare undiagnosed diseases in Chile
Rare diseases affect millions of people worldwide, and most have a genetic etiology. The incorporation of next-generation sequencing into clinical settings, particularly exome and genome sequencing, has resulted in an unprecedented improvement in diagnosis and discovery in the past decade. Nevertheless, these tools are unavailable in many countries, increasing health care gaps between high- and low-and-middle-income countries and prolonging the “diagnostic odyssey” for patients. To advance genomic diagnoses in a setting of limited genomic resources, we developed DECIPHERD, an undiagnosed diseases program in Chile. DECIPHERD was implemented in two phases: training and local development. The training phase relied on international collaboration with Baylor College of Medicine, and the local development was structured as a hybrid model, where clinical and bioinformatics analysis were performed in-house and sequencing outsourced abroad, due to lack of high-throughput equipment in Chile. We describe the implementation process and findings of the first 103 patients. They had heterogeneous phenotypes, including congenital anomalies, intellectual disabilities and/or immune system dysfunction. Patients underwent clinical exome or research exome sequencing, as solo cases or with parents using a trio design. We identified pathogenic, likely pathogenic or variants of unknown significance in genes related to the patients´ phenotypes in 47 (45.6%) of them. Half were de novo informative variants, and half of the identified variants have not been previously reported in public databases. DECIPHERD ended the diagnostic odyssey for many participants. This hybrid strategy may be useful for settings of similarly limited genomic resources and lead to discoveries in understudied populations.
- Open Access
- 6 September 2023
- Published by Springer Nature in Research Square
Decoding Complex Inherited Phenotypes in Rare Disorders: The DECIPHERD initiative for rare undiagnosed diseases in Chile.
Rare diseases affect millions of people worldwide, and most have a genetic etiology. The incorporation of next-generation sequencing into clinical settings, particularly exome and genome sequencing, has resulted in an unprecedented improvement in diagnosis and discovery in the past decade. Nevertheless, these tools are unavailable in many countries, increasing health care gaps between high- and low-and-middle-income countries and prolonging the “diagnostic odyssey” for patients. To advance genomic diagnoses in a setting of limited genomic resources, we developed DECIPHERD, an undiagnosed diseases program in Chile. DECIPHERD was implemented in two phases: training and local development. The training phase relied on international collaboration with Baylor College of Medicine, and the local development was structured as a hybrid model, where clinical and bioinformatics analysis were performed in-house and sequencing outsourced abroad, due to lack of high-throughput equipment in Chile. We describe the implementation process and findings of the first 103 patients. They had heterogeneous phenotypes, including congenital anomalies, intellectual disabilities and/or immune system dysfunction. Patients underwent clinical exome or research exome sequencing, as solo cases or with parents using a trio design. We identified pathogenic, likely pathogenic or variants of unknown significance in genes related to the patients´ phenotypes in 48 (46.6%) of them. Half were de novo informative variants, and half of the identified variants have not been previously reported in public databases. DECIPHERD ended the diagnostic odyssey for many participants. This hybrid strategy may be useful for settings of similarly limited genomic resources and lead to discoveries in understudied populations.
- 6 September 2023
- Published by Springer Nature in Research Square
Open AccessDecoding Complex Inherited Phenotypes in Rare Disorders: The DECIPHERD initiative for rare undiagnosed diseases in Chile.
Rare diseases affect millions of people worldwide, and most have a genetic etiology. The incorporation of next-generation sequencing into clinical settings, particularly exome and genome sequencing, has resulted in an unprecedented improvement in diagnosis and discovery in the past decade. Nevertheless, these tools are unavailable in many countries, increasing health care gaps between high- and low-and-middle-income countries and prolonging the “diagnostic odyssey” for patients. To advance genomic diagnoses in a setting of limited genomic resources, we developed DECIPHERD, an undiagnosed diseases program in Chile. DECIPHERD was implemented in two phases: training and local development. The training phase relied on international collaboration with Baylor College of Medicine, and the local development was structured as a hybrid model, where clinical and bioinformatics analysis were performed in-house and sequencing outsourced abroad, due to lack of high-throughput equipment in Chile. We describe the implementation process and findings of the first 103 patients. They had heterogeneous phenotypes, including congenital anomalies, intellectual disabilities and/or immune system dysfunction. Patients underwent clinical exome or research exome sequencing, as solo cases or with parents using a trio design. We identified pathogenic, likely pathogenic or variants of unknown significance in genes related to the patients´ phenotypes in 48 (46.6%) of them. Half were de novo informative variants, and half of the identified variants have not been previously reported in public databases. DECIPHERD ended the diagnostic odyssey for many participants. This hybrid strategy may be useful for settings of similarly limited genomic resources and lead to discoveries in understudied populations.
- Open Access
- 31 October 2022
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 79 (12) , 1267-1276
Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice
Genetic etiologies are responsible for seizures in up to 40% of children and 23% of adults with epilepsy.1-7 Early use of genetic testing for diagnosis and clinical management has been proposed; however, recommendations for genetic testing in individuals with epilepsy are currently limited.8-11 Additionally, estimates of how often a molecular diagnosis has clinically actionable implications have varied widely, from 60% in a single-center study12 to 20% in a multicenter study,13 although more recent studies estimate 50%.6,14,15 Studies of treatment approaches based on genetic diagnoses have shown improved outcomes in patients with epilepsy.1,5,7,12,16-19
- 31 October 2022
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 79 (12) , 1267-1276
Open AccessGenetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice
Genetic etiologies are responsible for seizures in up to 40% of children and 23% of adults with epilepsy.1-7 Early use of genetic testing for diagnosis and clinical management has been proposed; however, recommendations for genetic testing in individuals with epilepsy are currently limited.8-11 Additionally, estimates of how often a molecular diagnosis has clinically actionable implications have varied widely, from 60% in a single-center study12 to 20% in a multicenter study,13 although more recent studies estimate 50%.6,14,15 Studies of treatment approaches based on genetic diagnoses have shown improved outcomes in patients with epilepsy.1,5,7,12,16-19
- Open Access
Exome Sequencing Identifies Genetic Variants Associated with Extreme Manifestations of the Cardiovascular Phenotype in Marfan Syndrome
Marfan Syndrome (MFS) is an autosomal dominant condition caused by variants in the fibrillin-1 (FBN1) gene. Cardinal features of MFS include ectopia lentis (EL), musculoskeletal features and aortic root aneurysm and dissection. Although dissection of the ascending aorta is the main cause of mortality in MFS, the clinical course differs considerably in age of onset and severity, even among individuals who share the same causative variant, suggesting the existence of additional genetic variants that modify the severity of the cardiovascular phenotype in MFS. We recruited MFS patients and classified them into severe (n = 8) or mild aortic phenotype (n = 14) according to age of presentation of the first aorta-related incident. We used Exome Sequencing to identify the genetic variants associated with the severity of aortic manifestations and we performed linkage analysis where suitable. We found five genes associated with severe aortic phenotype and three genes that could be protective for this phenotype in MFS. These genes regulate components of the extracellular matrix, TGFβ pathway and other signaling pathways that are involved in the maintenance of the ECM or angiogenesis. Further studies will be required to understand the functional effect of these variants and explore novel, personalized risk management and, potentially, therapies for these patients.
Open AccessExome Sequencing Identifies Genetic Variants Associated with Extreme Manifestations of the Cardiovascular Phenotype in Marfan Syndrome
Marfan Syndrome (MFS) is an autosomal dominant condition caused by variants in the fibrillin-1 (FBN1) gene. Cardinal features of MFS include ectopia lentis (EL), musculoskeletal features and aortic root aneurysm and dissection. Although dissection of the ascending aorta is the main cause of mortality in MFS, the clinical course differs considerably in age of onset and severity, even among individuals who share the same causative variant, suggesting the existence of additional genetic variants that modify the severity of the cardiovascular phenotype in MFS. We recruited MFS patients and classified them into severe (n = 8) or mild aortic phenotype (n = 14) according to age of presentation of the first aorta-related incident. We used Exome Sequencing to identify the genetic variants associated with the severity of aortic manifestations and we performed linkage analysis where suitable. We found five genes associated with severe aortic phenotype and three genes that could be protective for this phenotype in MFS. These genes regulate components of the extracellular matrix, TGFβ pathway and other signaling pathways that are involved in the maintenance of the ECM or angiogenesis. Further studies will be required to understand the functional effect of these variants and explore novel, personalized risk management and, potentially, therapies for these patients.
- 1 July 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (4) , 405-411
Tenorio syndrome: Description of 14 novel cases and review of the clinical and molecular features
Tenorio syndrome (TNORS) (OMIM #616260) is a relatively recent disorder with very few cases described so far. Clinical features included macrocephaly, intellectual disability, hypotonia, enlarged ventricles and autoimmune diseases. Molecular underlying mechanism demonstrated missense variants and a large deletion encompassing RNF125, a gene that encodes for an U3 ubiquitin ligase protein. Since the initial description of the disorder in six patients from four families, several new patients were diagnosed, adding more evidence to the clinical spectrum. In this article we described 14 additional cases with deep phenotyping and make an overall review of all the cases with pathogenic variants in RNF125. Not all patients presented with overgrowth, but instead, most patients showed a common pattern of neurodevelopmental disease, macrocephaly and/or large forehead. Segregation analysis showed that, though the variant was inherited in some patients from an apparently asymptomatic parent, deep phenotyping suggested a mild form of the disease in some of them. The mechanism underlying the development of this disease is not well understood yet and the report of further cases will help to a better understanding and clinical characterization of the syndrome.
- 1 July 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (4) , 405-411
Tenorio syndrome: Description of 14 novel cases and review of the clinical and molecular features
Tenorio syndrome (TNORS) (OMIM #616260) is a relatively recent disorder with very few cases described so far. Clinical features included macrocephaly, intellectual disability, hypotonia, enlarged ventricles and autoimmune diseases. Molecular underlying mechanism demonstrated missense variants and a large deletion encompassing RNF125, a gene that encodes for an U3 ubiquitin ligase protein. Since the initial description of the disorder in six patients from four families, several new patients were diagnosed, adding more evidence to the clinical spectrum. In this article we described 14 additional cases with deep phenotyping and make an overall review of all the cases with pathogenic variants in RNF125. Not all patients presented with overgrowth, but instead, most patients showed a common pattern of neurodevelopmental disease, macrocephaly and/or large forehead. Segregation analysis showed that, though the variant was inherited in some patients from an apparently asymptomatic parent, deep phenotyping suggested a mild form of the disease in some of them. The mechanism underlying the development of this disease is not well understood yet and the report of further cases will help to a better understanding and clinical characterization of the syndrome.
- 4 May 2021
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 92 (2) , 309-315
Consenso de la Rama de Genética de la Sociedad Chilena de Pediatría sobre priorización de personas con Síndrome de Down y otras condiciones poco frecuentes en la Campaña de Vacunación COVID-19
En el marco de la campaña de vacunación contra el virus SARS-CoV-2, el Ministerio de Salud de Chile solicitó asesoría a la de Rama de Genética de la Sociedad Chilena de Pediatría, para definir el nivel de priorización para pacientes con Síndrome de Down. Un panel de Genetistas trabajó en el desarrollo de este consenso, en el cual se incluyeron no solo los pacientes con Síndrome de Down, sino que se amplió la búsqueda a pacientes con otros tipos de discapacidades, en edades tanto pediátricas como adultas con el fin de aportar al desarrollo de medidas de salud pública frente a la pandemia de la COVID-19. El consenso concluye que, dados los antecedentes epidemiológicos de comorbilidades asociadas al Síndrome de Down, la mayor incidencia de casos de infección grave en este grupo de la población y mayor mortalidad, se debe considerar a los individuos con Trisomía 21 como una población de alto riesgo, y por ende, la vacunación contra SARS-CoV-2 debe tener prioridad alta para todas las personas con Síndrome de Down independiente de su edad (salvo el límite establecido por los ensayos clínicos de cada vacuna), debiendo ser precedidas solo por los grupos de personal de la salud y adultos con ≥ 60-65 años. Así mismo este grupo de expertos insta a las autoridades de salud a incluir como población prioritaria a las personas con discapacidad intelectual y condiciones relacionadas (otras anomalías cromosómicas diferentes a Síndrome de Down, discapacidad intelectual, anomalías congénitas y condiciones causantes de discapacidad con microcefalia), así como a los cuidadores de personas con este tipo de patologías. La vacunación en niños con este tipo de enfermedades debiera considerarse como parte del primer grupo de prioridad, una vez se disponga de vacunas contra SARS-CoV-2 seguras para ser empleadas en los niños, niñas y adolescentes.
- 4 May 2021
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 92 (2) , 309-315
Consenso de la Rama de Genética de la Sociedad Chilena de Pediatría sobre priorización de personas con Síndrome de Down y otras condiciones poco frecuentes en la Campaña de Vacunación COVID-19
En el marco de la campaña de vacunación contra el virus SARS-CoV-2, el Ministerio de Salud de Chile solicitó asesoría a la de Rama de Genética de la Sociedad Chilena de Pediatría, para definir el nivel de priorización para pacientes con Síndrome de Down. Un panel de Genetistas trabajó en el desarrollo de este consenso, en el cual se incluyeron no solo los pacientes con Síndrome de Down, sino que se amplió la búsqueda a pacientes con otros tipos de discapacidades, en edades tanto pediátricas como adultas con el fin de aportar al desarrollo de medidas de salud pública frente a la pandemia de la COVID-19. El consenso concluye que, dados los antecedentes epidemiológicos de comorbilidades asociadas al Síndrome de Down, la mayor incidencia de casos de infección grave en este grupo de la población y mayor mortalidad, se debe considerar a los individuos con Trisomía 21 como una población de alto riesgo, y por ende, la vacunación contra SARS-CoV-2 debe tener prioridad alta para todas las personas con Síndrome de Down independiente de su edad (salvo el límite establecido por los ensayos clínicos de cada vacuna), debiendo ser precedidas solo por los grupos de personal de la salud y adultos con ≥ 60-65 años. Así mismo este grupo de expertos insta a las autoridades de salud a incluir como población prioritaria a las personas con discapacidad intelectual y condiciones relacionadas (otras anomalías cromosómicas diferentes a Síndrome de Down, discapacidad intelectual, anomalías congénitas y condiciones causantes de discapacidad con microcefalia), así como a los cuidadores de personas con este tipo de patologías. La vacunación en niños con este tipo de enfermedades debiera considerarse como parte del primer grupo de prioridad, una vez se disponga de vacunas contra SARS-CoV-2 seguras para ser empleadas en los niños, niñas y adolescentes.
- 21 November 2020
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 184 (4) , 986-995
Skeletal dysplasias in Latin America
Skeletal dysplasias (SD) are disturbances in growth due to defects intrinsic to the bone and/or cartilage, usually affecting multiple bones and having a progressive character. In this article, we review the state of clinical and research SD resources available in Latin America, including three specific countries (Brazil, Argentina, and Chile), that have established multidisciplinary clinics for the care of these patients. From the epidemiological point of view, the SD prevalence of 3.2 per 10,000 births from nine South American countries included in the ECLAMC network represents the most accurate estimate not just in Latin America, but worldwide. In Brazil, there are currently five groups focused on SD. The data from one of these groups including the website www.ocd.med.br, created to assist in the diagnosis of SD, are highlighted showing that telemedicine for this purpose represents a good strategy for the region. The experience of more than 30 years of the SD multidisciplinary clinic in an Argentinian Hospital is presented, evidencing a solid experience mainly in the follow‐up of the most frequent SD, especially those belonging the FGFR3 group and OI. In Chile, a group with 20 years of experience presents its work with geneticists and pediatricians, focusing on diagnostic purposes and clinical management. Altogether, although SD health‐care and research activities in Latin America are in their early stages, the experience in these three countries seems promising and stimulating for the region as a whole.
- 21 November 2020
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 184 (4) , 986-995
Skeletal dysplasias in Latin America
Skeletal dysplasias (SD) are disturbances in growth due to defects intrinsic to the bone and/or cartilage, usually affecting multiple bones and having a progressive character. In this article, we review the state of clinical and research SD resources available in Latin America, including three specific countries (Brazil, Argentina, and Chile), that have established multidisciplinary clinics for the care of these patients. From the epidemiological point of view, the SD prevalence of 3.2 per 10,000 births from nine South American countries included in the ECLAMC network represents the most accurate estimate not just in Latin America, but worldwide. In Brazil, there are currently five groups focused on SD. The data from one of these groups including the website www.ocd.med.br, created to assist in the diagnosis of SD, are highlighted showing that telemedicine for this purpose represents a good strategy for the region. The experience of more than 30 years of the SD multidisciplinary clinic in an Argentinian Hospital is presented, evidencing a solid experience mainly in the follow‐up of the most frequent SD, especially those belonging the FGFR3 group and OI. In Chile, a group with 20 years of experience presents its work with geneticists and pediatricians, focusing on diagnostic purposes and clinical management. Altogether, although SD health‐care and research activities in Latin America are in their early stages, the experience in these three countries seems promising and stimulating for the region as a whole.
- Open Access
- 1 August 2020
- Published by Instituto Mexicano del Seguro Social in Revista chilena de obstetricia y ginecología
- Vol. 85 (4) , 358-365
Diagnóstico prenatal de malformaciones congénitas y alteraciones cromosómicas: resultado de la experiencia CIMAF - Hospital Dr. Sótero Del Río
Palabras claves: malformaciones congénitas; diagnostico prenatal; equipo multidisciplinario
- 1 August 2020
- Published by Instituto Mexicano del Seguro Social in Revista chilena de obstetricia y ginecología
- Vol. 85 (4) , 358-365
Open AccessDiagnóstico prenatal de malformaciones congénitas y alteraciones cromosómicas: resultado de la experiencia CIMAF - Hospital Dr. Sótero Del Río
Palabras claves: malformaciones congénitas; diagnostico prenatal; equipo multidisciplinario